Francesca Trojsi

Francesca Trojsi

Associate Professor of Neurology, Referent of the ALS Centre of the First Division of Neurology

Francesca Trojsi is Associate Professor of Neurology at the University of Campania “Luigi Vanvitelli” in Naples (Italy) and Referent of the ALS Centre of University Hospital “Luigi Vanvitelli” in Naples  (Italy). She had a Research Fellow at the “MRI  Research  Center  SUN-FISM” (Second  University  of Naples – Naples, Italy), from 2009 to 2010, and was PhD in “Experimental  Physiopathology  and  Neurosciences” (Second  University  of Naples, Naples, Italy) performing the PhD research project “Structural and functional markers in Amyotrophic Lateral Sclerosis (ALS) as detected by advanced neuroimaging techniques”. She was Assistant Professor of Neurology at the University of Campania “Luigi Vanvitelli” in Naples (Italy) from 2014 to 2021. She is Associate  Editor of  the section “Neurodegeneration” of “Frontiers in Neuroscience” (2014-today), and of “Orphanet Journal of Rare Diseases” (2021-today). She is Academic Editor of “Brain Sciences” (MDPI) (2020-today). Her main areas of research are neuroimaging/clinical trials applied to ALS and dementia. She is member of the EUROPEAN REFERENCE NETWORK (ERN) Euro Neuromuscular Disorders (NMD) within the Healthcare Provider University Hospital “Luigi Vanvitelli” (2016-today) and member of the Italian ALS Genetic (ITALSGEN) Consortium (2012-today) and of the Neuroimaging  Society  in Amyotrophic  Lateral  Sclerosis (NiSALS) (2014-today).

Connect
Connect trials
Recruiting
Phase iii

PHOENIX trial

Industry trial

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.

Read more
Active
Phase iii

ADORE trial

Industry trial

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).

Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.

Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.

Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more